For the
quarter ending March 2022, standalone net sales (including other operating income) of Pfizer has increased 2.79% to Rs 549.66 crore compared to quarter ended march 2021.
Operating profit margin has jumped from 23.51% to 30.10%, leading to 31.58% rise in operating profit to Rs 165.45 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 18.61% to 13.03%. Purchase of finished goods cost rose from 9.19% to 31.79%. Employee cost decreased from 20.20% to 14.15%. Other expenses fell from 25.22% to 15.67%. Other income fell 53.98% to Rs 17.12 crore. PBIDT rose 12.05% to Rs 182.57 crore. Provision for interest up 8.76% to Rs 3.85 crore. Loan funds declined from Rs 63.23 crore as of 31 March 2021 to Rs 39.25 crore as of 31 March 2022. Inventories rose to Rs 448.90 crore as of 31 March 2022 from Rs 435.05 crore as of 31 March 2021. Sundry debtors were higher at Rs 124.27 crore as of 31 March 2022 compared to Rs 108.77 crore as of 31 March 2021. Cash and bank balance rose to Rs 1,633.33 crore as of 31 March 2022 from Rs 1,115.10 crore as of 31 March 2021. PBDT rose 12.12% to Rs 178.72 crore. Provision for depreciation rose 23.07% to Rs 33.61 crore. Fixed assets increased to Rs 248.24 crore as of 31 March 2022 from Rs 224.70 crore as of 31 March 2021. Intangible assets declined from Rs 672.36 crore to Rs 622.04 crore. Profit before tax grew 9.86% to Rs 145.11 crore. Provision for tax was expense of Rs 19.32 crore, compared to Rs 31.54 crore. Effective tax rate was 13.31% compared to 23.88%. Profit after tax rose 25.10% to Rs 125.79 crore. Equity capital stood at Rs 45.75 crore as of 31 March 2022 to Rs 45.75 crore as of 31 March 2021. Per share face Value remained same at Rs 10.00. Promoters’ stake was 63.92% as of 31 March 2022 ,compared to 63.92% as of 31 March 2021 .
Full year results analysis
Net sales (including other operating income) of Pfizer has increased 16.64% to Rs 2,610.99 crore. Operating profit margin has jumped from 31.81% to 32.01%, leading to 17.36% rise in operating profit to Rs 835.73 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.05% to 13.20%. Purchase of finished goods cost rose from 20.17% to 24.84%. Employee cost decreased from 16.23% to 15.04%. Other expenses fell from 16.53% to 15.78%. Other income fell 22.77% to Rs 62.65 crore. PBIDT rose 13.25% to Rs 898.38 crore. Provision for interest fell 30.58% to Rs 10.49 crore. Loan funds declined from Rs 63.23 crore as of 31 March 2021 to Rs 39.25 crore as of 31 March 2022. Inventories rose to Rs 448.90 crore as of 31 March 2022 from Rs 435.05 crore as of 31 March 2021. Sundry debtors were higher at Rs 124.27 crore as of 31 March 2022 compared to Rs 108.77 crore as of 31 March 2021. Cash and bank balance rose to Rs 1,633.33 crore as of 31 March 2022 from Rs 1,115.10 crore as of 31 March 2021. PBDT rose 14.11% to Rs 887.89 crore. Provision for depreciation rose 5.11% to Rs 115 crore. Fixed assets increased to Rs 248.24 crore as of 31 March 2022 from Rs 224.70 crore as of 31 March 2021. Intangible assets declined from Rs 672.36 crore to Rs 622.04 crore. Profit before tax grew 15.58% to Rs 772.89 crore. Provision for tax was expense of Rs 160.33 crore, compared to Rs 171.11 crore. Effective tax rate was 20.74% compared to 25.59%. Profit after tax rose 23.10% to Rs 612.56 crore. Equity capital stood at Rs 45.75 crore as of 31 March 2022 to Rs 45.75 crore as of 31 March 2021. Per share face Value remained same at Rs 10.00. Promoters’ stake was 63.92% as of 31 March 2022 ,compared to 63.92% as of 31 March 2021 . Cash flow from operating activities increased to Rs 667.08 crore for year ended March 2022 from Rs 427.33 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 15.31 crore, compared to Rs 17.70 crore during the year ended March 2021.
Dividend update
The Board of Directors has recommended a dividend of Rs 35
per equity share of Rs 10 each (350%) for the year ended March 31, 2022. The
said dividend (subject to approval) shall be paid on or before September 23,
2022.
| Pfizer : Standalone Results | | Quarter ended | Year ended |
|---|
| Particulars | 202203 | 202103 | Var.(%) | 202203 | 202103 | Var.(%) |
|---|
| Net Sales (including other operating income) | 549.66 | 534.76 | 2.79 | 2,610.99 | 2,238.55 | 16.64 | | OPM (%) | 30.10 | 23.51 | 659 bps | 32.01 | 31.81 | 20 bps | | OP | 165.45 | 125.74 | 31.58 | 835.73 | 712.12 | 17.36 | | Other Inc. | 17.12 | 37.20 | -53.98 | 62.65 | 81.12 | -22.77 | | PBIDT | 182.57 | 162.94 | 12.05 | 898.38 | 793.24 | 13.25 | | Interest | 3.85 | 3.54 | 8.76 | 10.49 | 15.11 | -30.58 | | PBDT | 178.72 | 159.40 | 12.12 | 887.89 | 778.13 | 14.11 | | Depreciation | 33.61 | 27.31 | 23.07 | 115 | 109.41 | 5.11 | | PBT | 145.11 | 132.09 | 9.86 | 772.89 | 668.72 | 15.58 | | PBT before EO | 145.11 | 132.09 | 9.86 | 772.89 | 668.72 | 15.58 | | EO Income | 0 | 0 | - | 0 | 0 | - | | PBT after EO | 145.11 | 132.09 | 9.86 | 772.89 | 668.72 | 15.58 | | Taxation | 19.32 | 31.54 | -38.74 | 160.33 | 171.11 | -6.30 | | PAT | 125.79 | 100.55 | 25.10 | 612.56 | 497.61 | 23.10 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 125.79 | 100.55 | 25.10 | 612.56 | 497.61 | 23.10 | | EPS (Rs)* | 27.50 | 21.98 | 25.10 | 133.90 | 108.77 | 23.10 | | | * EPS is on current equity of Rs 45.75 crore, Face value of Rs 10, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|